1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Dr. Reddy’s Secures First Generic Semaglutide Approval in Canada

30 Apr 2026
Admin
News Article

Dr. Reddy’s Secures First Generic Semaglutide Approval in Canada—Beating the Clock

Speed matters in generics. Being first matters more. Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic semaglutide injection—becoming the first company to secure market authorization in the country, and ahead of the regulator’s target review date.

What’s Been Approved

The authorization covers two pen strengths:

2 mg/pen (1.34 mg/mL)
4 mg/pen (1.34 mg/mL)

This puts Dr. Reddy’s in a strong position to compete across key dosing segments in the GLP-1 market.

Why This Is a Big Deal?

Canada is not a small play in semaglutide.

Second-largest global market for semaglutide
~3.9 million people living with diagnosed diabetes
~6% of adults with prediabetes

According to the Public Health Agency of Canada, these numbers are expected to rise as the population ages.

That creates a simple equation: growing demand + high-cost therapies = opportunity for generics.

The Science Behind the Market

Semaglutide belongs to the GLP-1 receptor agonist class—one of the most clinically validated categories in diabetes care.

Improves glycaemic control (HbA1c reduction)
Supported by extensive global clinical evidence
Increasingly used in comprehensive diabetes management

This is not a fringe therapy. It’s becoming standard of care.

How Dr. Reddy’s Pulled It Off

This approval highlights a few critical capabilities:

In-house API production (full control over peptide synthesis)
Strong formulation development expertise
Execution in complex generics and biologically derived molecules

The finished product is currently manufactured with support from OneSource Specialty Pharma, indicating a hybrid manufacturing model.

Strategic Implications

This isn’t just a regulatory win. It’s a positioning move.

First-to-market advantage in generic semaglutide in Canada
Early access to a high-growth therapeutic category
Strengthening footprint in regulated markets

And importantly, it reinforces Dr. Reddy’s push into peptide-based therapeutics—a space with high barriers and high rewards.

Leadership Perspective

CEO Erez Israeli framed the approval as a milestone in the company’s GLP-1 journey, highlighting:

Expertise in peptide science
Ability to meet stringent global regulatory standards
Commitment to consistent supply and affordability

Translation: this is a long-term play, not a one-off launch.

What This Signals for the Industry

Three trends are becoming clear:

Peptide generics are going mainstream
Speed to approval is a competitive weapon
Integrated capabilities (API + formulation) are non-negotiable

Bottom Line

Dr. Reddy’s didn’t just enter the semaglutide market in Canada, it set the pace. First approval. Early entry. Strong technical backbone. Now the real question: how long before competitors catch up?